All Articles

As private credit pulls back, PropTech firm Gumption expands its tech-driven financing platform to the West Coast, betting on a seasoned expert to succeed.

Polaris appoints Sealed Air CEO Dustin Semach to its board, a move signaling a calculated pivot towards technology and financial rigor in its powersports strategy.

A new AI platform, born from its founder's own cancer battle, aims to give patients the tools to navigate complex treatments and advocate for their own care.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

In a cooling life science real estate market, a major lease for advanced manufacturing highlights the rise of radiopharmaceuticals and Boston's enduring industrial might.

As travelers trade mega-resorts for meaningful moments, Azamara Cruises bets its future on a simple idea: the next big thing is small. Here's the strategy.

With new funding from top VCs, DropGenie is shrinking gene editing to power the next wave of AI-driven drug discovery using precious patient cells.

A new high-tech distribution center in Italy reveals the strategy for modern market dominance: a fusion of aggressive retail expansion and radical sustainability.

XTEL's new SAP Store integration dissolves the trade-off between deep ERP integration and best-in-class tools, deploying agentic AI to reshape CPG profitability.

Brunswick Corp. promises 'multi-million-dollar savings' from operational shifts at its Lowell plant. But behind the corporate buzzwords, a community weighs the price of efficiency.

Chain's new AI agent automates the complex, conversational dance of freight booking. It's a move that promises not to replace brokers, but to redefine their role.

NH is investing millions in a statewide data grid for its schools, translating military precision into an invisible network designed to protect every student.

Little Caesars’ new Spider-Man partnership is more than a pizza promotion; it's a calculated bid for cultural supremacy in the fast-food wars.

The explosion welding leader is diversifying into weld overlay, a strategic move to offer turnkey solutions for aging industrial assets in harsh environments.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

SKS's new Boston Technicurean Center isn't just a showroom; it's a destination. Explore how this partnership is changing how we design, buy, and live.

A new partnership aims to end digital anonymity by tying every network action, including those by AI, back to a biometrically verified human authority.

A Chinese AI innovator and a new European biotech just sealed a massive deal. It’s a blueprint for the future of medicine, where technology and strategy unite for patients.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

The NYSE owner is betting its financial infrastructure can solve the carbon market's trust problem, turning credits into an institutional asset class.